What is Synairgen?
Synairgen plc is a biopharmaceutical company dedicated to the discovery and development of novel treatments for respiratory diseases. The company's lead candidate, SNG001, is an inhaled interferon beta formulation designed for severe viral lung infections, currently in pre-clinical development. Interferon beta, a naturally occurring protein, plays a crucial role in modulating the immune system's response to viral pathogens, including coronaviruses, positioning Synairgen at the forefront of addressing significant unmet medical needs in respiratory health.
How much funding has Synairgen raised?
Synairgen has raised a total of $34.5M across 2 funding rounds:
Stock Offering
$12.5M
Other Financing Round
$22M
Stock Issuance/Offering (2004): $12.5M, investors not publicly disclosed
Other Financing Round (2025): $22M led by Tetragon Financial Group
Key Investors in Synairgen
Tetragon Financial Group
Tetragon is a global investment firm specializing in alternative assets, with a focus on long-term, resilient performance across diverse strategies. With over 20 years of experience, the firm employs an innovative investment approach to extract alpha and compound value over time.
What's next for Synairgen?
The recent major strategic investment signifies a pivotal moment for Synairgen, likely enabling the acceleration of its drug development pipeline, particularly for SNG001. This infusion of capital is expected to support further clinical trials, regulatory submissions, and potential commercialization efforts. The company's focus on severe viral lung infections and its platform technology suggest a trajectory aimed at scaling its operations and solidifying its market position within the biotechnology sector.
See full Synairgen company page
